<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542879662903">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">22.11.2018 09:41:02 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.1j5x1ciiwpaly</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>I enjoy travelling &lt;a href=&quot;https://accentresurfacing.com/wwwcygnethealthcouk-stevenage-4110.pdf#garbage&quot;&gt;www.cygnethealth.co.uk harrogate&lt;/a&gt;  The company&amp;#39;s 184-patient study showed that the oral med provided a statistically significant improvement in lung function over placebo, with fewer adverse events in the treatment camp versus those on placebo. Specifically, the Phase II study found a 3.9% improvement in the FEV1 test in those taking 200 mg of ARRY-502 twice a day versus placebo. A 6.8% improvement was found in patients with certain levels of the TH2 biomarker associated with allergic asthma.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
